antiplatelet

The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.

The nanoparticles "hold immense potential to be promoted as an antiplatelet agent, " the researchers note.

Antiplatelet therapy is one of the important measures in the secondary prevention of ischemic stroke.

They did not find nearly as strong a link between antiplatelet agents and ICH as that between anticoagulation and hemorrhages , she added.

The authors recommended that intensified antiplatelet therapy might be indicated for type 2 diabetic patients.

Current therapies for arterial ischemic stroke include thrombolytic, antithrombotic and antiplatelet agents, blood transfusion and surgery.

The researchers found the risks of developing preeclampsia dropped 10 percent among women taking aspirin or other antiplatelet medications.

The search for a useful clinical laboratory diagnostic assay for the antiplatelet antibodies has been long and difficult.

Aspirin is an effective antiplatelet drug with proven benefit in the primary and secondary prevention of coronary heart disease.

The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy.

Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events : More " Advanced " Drug, More Perfect ?

What are the factors that may guide the decision to select a specific antiplatelet agent to initiate first after ischemic stroke?

Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.

Title: Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?

New drugs and new technologies, especially antiplatelet and regulation of lipid metabolism are emerging and applying in clinical practice.

Clinical trial of antithrombotic therapy became the high points, some hopeful new antiplatelet drugs and anticoagulants made their debuts.

These findings underscore the need of individualized antiplatelet treatment regimens in diabetic patients.

Prolonged antiplatelet therapy with clopidogrel is mandatory after implantation of drug-eluting stents.

Objective To assess the activity in blood clotting and antiplatelet aggregation of dragon blood from different habitats.

On-TIME 2 is an important study that gives a number of insights into optimising the antiplatelet regimen in primary PCI.

International Circulation: Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?

Objective To observe the influence of proton pump inhibitor(PPI) esomeprazole on antiplatelet effect of clopidogrel.

There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.

Cilostazol, the model drug of this study, is a synthetic antiplatelet agent with vasodilating effect.

Warfarin is substantially more efficacious (by approximately 40%) than antiplatelet therapy.

In patients at low risk of GI bleeding, however, the balance of risk and benefit tips away from using PPIs together with antiplatelet drugs.

Antiplatelet agents are not as effective as warfarin in reducing the risk of thromboembolism in patients with AF.

Antiplatelet nonspecific antibody and neonatal platelets are more closely related to reduce rates, a statistically significant (P 05).

So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder.

We speculate that in the later cohort clinicians were more aware of the risk of DES and prolonged antiplatelet therapy.

But these antiplatelet drugs also increase the risk of bleeding, including upper GI bleeding.

Aspirin is the sole evidence-based antiplatelet drug for treatment of acute ischemic stroke.

Conclusions: Currently, eptifibatide is used as the adjunct antiplatelet agent in the majority of patients undergoing primary PCI.

Novel and more potent antiplatelet agents currently under clinical development will be useful in efforts to reach these therapeutic goals.

Antiplatelet agents play a major role in thrombus prevention and cure.

In the future, antiplatelet therapy will likely be tailored for the individual patient, they note.

Among those with late and very late ST, the prevalence of dual-antiplatelet therapy was 57% and 36%, respectively.

In my opinion, it is not with triple therapy that we can solve this problem but with alternative antiplatelet agents.

Conclusion: Nearly 4 of 10 patients receiing warfarin management care were receiing warfarin and antiplatelet combination therapy.

Antiplatelet Therapy Necessary at Least a Year with Drug-Eluting Stents

Efficacy of intervention with statins and antiplatelet drugs for carotid arteriosclerosis in patients with ischemic cerebrovascular diseases

Expression and significance of platelet membrane glycoproteins and antiplatelet antibody in patients with anaphylactoid purpura

A study on the synthesis and anti-tumor, antiplatelet activity relationships between genistein and its two derivatives

The in vitro antiplatelet aggregative effects of Honeysuckle and its organic acid compounds

Analysis the relation of anticoagulant and antiplatelet treatment with intracranial hemorrhage

Current status of antiplatelet therapy after percutaneous coronary intervention

Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention

Triple antiplatelet therapy no better than dual therapy

Application of Antiplatelet and Anticoagulation Drugs in Cardio-Cerebral Vascular Diseases

Study on Inhibitory Effect of Antiplatelet Drugs on Atherosclerosis and its Mechanism

Anticoagulative and antiplatelet therapy for pre and post coronary intervention treatment

Antiplatelet Therapy vs Lovenox plus Antiplatelet therapy for patients with increased risk of Stent Thrombosis

Prevention of Ischemic Stroke: Treatment of Anticoagulation and Antiplatelet

Impact of atorvastatin on the antiplatelet activity of clopidogrel in patients with acute coronary syndromes

Antiplatelet therapy in treatment of acute coronary syndrome during non intervention period

Antiplatelet therapy in patients with coronary artery disease during interventional perioperation

The effects of antiplatelet drugs on aggregation of platelet in patient with acute myocardial infarction

A clinical study in elderly patients treated with aspirin with different doses for antiplatelet therapy

delaying elective procedures until an appropriate course of antiplatelet therapy has been completed;

The Status and Progress of Antiplatelet Therapy In Ischemic Cerebrovascular Disease

The effect of antiplatelet congestion in patients with chronic obstructive pulmonary disease exacerbation

Consideration of consensus from ESC specialistsis involvement in new antiplatelet preparations

Response to antiplatelet treatment: from genes to outcome Betti Giusti, Rosanna Abbate

The Clinical Progress of Antiplatelet Agents in Patients with Coronary Artery Disease

Dual antiplatelet therapy for prevention of recurrent Ischemic events

Antiplatelet therapy for coronary artery disease: hot topics and prospects

Resistance of Aspirin in Antiplatelet--Aspirin Resistance

Effect of antiplatelet drugs on the incidence of restenosis after percutaneous transluminal coronary angioplasty and in-stent implantation

Research Progress of Antiplatelet Drug for Secondary Prevention of Stroke

The effect of antiplatelet drugs on nitric oxide synthase activity after coronary occlusion and reperfusion

Antiplatelet Therapy in the Secondary Prevention of Ischemic Stroke

Effect of Shule Capsule on the antiplatelet aggregation and antithrombotic in rats

African American Antiplatelet Stroke Prevention Study, AAASPS

The roles of Antiplatelet Agents in the Prevention and Treatment of Ischemic Stroke

Effect of antiplatelet drugs in ischemic cerebral vascular disease

Antiplatelet Therapy in Acute Cerebral Ischemia

Clongning and Expression of Antiplatelet Peptide in Escherichia Coli